Effects of Ondansetron versus Amantadine on fatigability in patients with multiple sclerosis

Effects of Ondansetron versus Amantadine on fatigability in patients with multiple sclerosis: a randomized clinical trial

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT20120215009014N250

Enrollment

104

Registered

2018-11-20

Start date

2018-11-06

Completion date

Unknown

Last updated

2019-01-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Multiple sclerosis. Multiple sclerosis

Interventions

Intervention 1: Intervention group: Tablet Ondansetron 4 mg twice a day for 4 weeks. Intervention 2: Control group: Capsule Amantadine 100 mg twice a day for 4 weeks.

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: Age of 18 to 65 years; Multiple sclerosis; Complaining of fatigability The ability to walk without assistance for at least 100 meters; FSS score of equal to or greater than 28

Exclusion criteria

Exclusion criteria: Systemic disease such as cardiovascular diseases, infection, thyroid disease, or vasculitis

Design outcomes

Primary

Measure	Time frame
Assessing the fatigability. Timepoint: Before and 4 weeks after treatment. Method of measurement: Using a standard questionnaire.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactAshkan Karvan

Hamedan University of Medical Sciences

karevanashkan2@gmail.com+98 81 3827 4184

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026